Skip to content

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00925925
Enrollment
64
Registered
2009-06-22
Start date
2009-06-30
Completion date
2012-05-31
Last updated
2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunodeficiency, Low Birth Weight, Small for Gestational Age

Keywords

Low birth weight, small for gestational age, B-cell function, epigenetics, B1a, B1b, CD19, CD5

Brief summary

Low birth weight (LBW) status (\< 10% for gestational age at birth) is associated with increased risk for diseases such as type II diabetes mellitus, hypertension, chronic obstructive pulmonary disease and coronary artery disease in adults, and represents one example of the fetal onset of adult disease hypothesis. Recent data strongly associates LBW status with impaired innate and adaptive immunity leading to increased risk for severe infections during adolescence or early adulthood. Animal studies suggest that the ratio of certain B lymphocyte subpopulations, the B1a and B1b cells, determines whether deficits in immunity occur. This study will determine the ratio of B1b to B1a lymphocyte subpopulations in the cord blood of infants born LBW in the late preterm to term gestations (\> 34 weeks at birth) and compare those ratios with those of normal birth weight (NBW) controls in a nested case control study design. Furthermore, animal studies suggest that the expression patterns of CD5 and CD19 proteins determines the cellular phenotype of the B lymphocyte, that of a B1a or a B1b cell, and that the regulatory regions controlling their expression are epigenetically vulnerable. The investigators will therefore isolate DNA and RNA from both B lymphocyte subpopulations and determine whether epigenetic changes to the regulatory regions of the genes coding for CD5 and CD19 protein expression occur in LBW lymphocyte subpopulations as compared to the lymphocytes from NBW infants. This proposal will be the first human study to examine epigenetic determination of a maladaptive phenotype following LBW status at birth in a specific cell type leading to a specific impairment of innate and adaptive immunity.

Interventions

OTHERCord blood collection for analysis

Cord blood will be collected from the placentas at delivery for analysis

Sponsors

Department of Health and Human Services
CollaboratorFED
University of Utah
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 2 Hours
Healthy volunteers
Yes

Inclusion criteria

* Infants delivered at University of Utah Health Sciences Center * For LBW group: * Gestational age \> or = to 34 0/7 weeks * Birth weight \< or = to 10% for gestational age * For NBW group: * Term infant controls delivered without complication * Adequate cord blood sample obtained directly after birth * Parents or guardians must have signed informed consent

Exclusion criteria

* Infants with major congenital anomalies will be excluded

Design outcomes

Primary

MeasureTime frame
Characterize and compare the Low Birth Weight(LBW) B lymphocyte subtype B1b with that of Normal Birth Weight(NBW) infants.2 years

Secondary

MeasureTime frame
Characterize CD19 and CD5 epigenetic regulation in LBW infants as compared to NBW infants.2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026